TY - JOUR
T1 - Proteome-Wide Analysis of Autoantibodies in Open-Angle Glaucoma in Japanese Population
T2 - A Pilot Study
AU - Takada, Naoko
AU - Ishikawa, Makoto
AU - Sato, Kota
AU - Kunikata, Hiroshi
AU - Ninomiya, Takahiro
AU - Hanyuda, Akiko
AU - Fukuda, Eriko
AU - Yamaguchi, Kei
AU - Ono, Chihiro
AU - Kirihara, Tomoko
AU - Shintani, Chie
AU - Tsusu, Chihiro
AU - Osanai, Aki
AU - Goshima, Naoki
AU - Izumi, Yukitoshi
AU - Zorumski, Charles F.
AU - Nakazawa, Toru
N1 - Publisher Copyright:
© 2025 by the authors.
PY - 2025/3
Y1 - 2025/3
N2 - Objectives: The objective of this study was to identify novel autoantibodies specific for open-angle glaucoma (OAG), including normal-tension glaucoma (NTG) and primary open-angle glaucoma (POAG), using proteome-wide autoantibody screening and to determine their utility for diagnosis. Methods: We conducted proteome-wide autoantibody screening by wet protein arrays. Autoantibody reactivity in the plasma of OAG patients (50 NTG and 69 POAG patients) was quantitatively analyzed and compared to that of controls (35 cataract patients). The area under the curve (AUC) of the receiver operating characteristic (ROC) and multivariate analyses were used to determine diagnostic potential in patients with OAG. Results: Based on differences in autoantibody titers and positivity rates, four autoantibodies against ETNK1, VMAC, NEXN, and SUN1 were selected as potential biomarkers to discriminate OAG and cataract. In discrimination between POAG and cataract, the AUCs of ETNK1 and VMAC were calculated to be 0.820 (95%CI: 0.733–0.907) and 0.889 (95%CI: 0.818–0.959), respectively. Furthermore, the combination of these four antibodies demonstrated diagnostic potential for OAG with an AUC of 0.828 (95%CI: 0.757–0.898) by multivariate analysis. Conclusions: Four new glaucoma-associated autoantibodies were identified in this study. The differences in autoantibody patterns in the plasma between glaucoma and cataract patients support their potential utility as biomarkers for glaucoma screening.
AB - Objectives: The objective of this study was to identify novel autoantibodies specific for open-angle glaucoma (OAG), including normal-tension glaucoma (NTG) and primary open-angle glaucoma (POAG), using proteome-wide autoantibody screening and to determine their utility for diagnosis. Methods: We conducted proteome-wide autoantibody screening by wet protein arrays. Autoantibody reactivity in the plasma of OAG patients (50 NTG and 69 POAG patients) was quantitatively analyzed and compared to that of controls (35 cataract patients). The area under the curve (AUC) of the receiver operating characteristic (ROC) and multivariate analyses were used to determine diagnostic potential in patients with OAG. Results: Based on differences in autoantibody titers and positivity rates, four autoantibodies against ETNK1, VMAC, NEXN, and SUN1 were selected as potential biomarkers to discriminate OAG and cataract. In discrimination between POAG and cataract, the AUCs of ETNK1 and VMAC were calculated to be 0.820 (95%CI: 0.733–0.907) and 0.889 (95%CI: 0.818–0.959), respectively. Furthermore, the combination of these four antibodies demonstrated diagnostic potential for OAG with an AUC of 0.828 (95%CI: 0.757–0.898) by multivariate analysis. Conclusions: Four new glaucoma-associated autoantibodies were identified in this study. The differences in autoantibody patterns in the plasma between glaucoma and cataract patients support their potential utility as biomarkers for glaucoma screening.
KW - autoantibody
KW - open-angle glaucoma
KW - proteome-wide analysis
UR - https://www.scopus.com/pages/publications/105000937188
U2 - 10.3390/biomedicines13030718
DO - 10.3390/biomedicines13030718
M3 - Article
C2 - 40149693
AN - SCOPUS:105000937188
SN - 2227-9059
VL - 13
JO - Biomedicines
JF - Biomedicines
IS - 3
M1 - 718
ER -